Media.Player

A GENE EXPRESSION SIGNATURE THAT REPRESENTS THE ACTIVATION OF THE KRAS ONCOGENE IN HUMAN CELLS

Technology Benefits

lung cancer

Technology Application

The KRAS activation signature can be used as a part of clinical test to characterize tumors of individual patients across multiple tumor types for prognostic and therapeutic purposes. Moreover, this test can be used for risk assessment of tumor development and as an early cancer marker. The use of expression signature profile has an advantage over tests that screen for specific mutations. Using this method activation of RAS pathway can be detected in tumors where no known KRAS mutations could be identified.

Detailed Technology Description

One of the goals of modern cancer research is to develop simple and robust methods that can accurately detect cellular pathways that are aberrantly regulated in individual tumor samples. The use of specific tumor markers or expression-based signatures is an effective way of tumor classification. Using gene expression arrays for the comparison of KRAS oncogenic versus wild type expressing human cell lines, the Dana Farber investigators identified a 300-gene expression signature that represents activation of the KRAS oncogene in human samples. Method utilizing this signature was used to identify lung tumors with KRAS mutations. The invention represents an accurate, universal and representative score of the activation of the KRAS oncogene and the RAS pathway, and use of such biological signature in the screening, prevention, diagnosis, therapy, monitoring and prognosis of cancer.

Supplementary Information

Inventor: HAHN, William C. | TAMAYO, Pablo | BOEHM, Jesse S. | MESIROV, Jill P.
Priority Number: WO2012075069A3
IPC Current: G01N0033574 | C12Q000168 | G06F001710 | G06F001910
Assignee Applicant: Dana-Farber Cancer Institute Inc.
Title: SIGNATURES AND DETERMINANTS ASSOCIATED WITH CANCER AND METHODS OF USE THEREOF | SIGNATURES ET DÉTERMINANTS ASSOCIÉS AU CANCER ET LEURS MÉTHODES D'UTILISATION
Usefulness: SIGNATURES AND DETERMINANTS ASSOCIATED WITH CANCER AND METHODS OF USE THEREOF | SIGNATURES ET DÉTERMINANTS ASSOCIÉS AU CANCER ET LEURS MÉTHODES D'UTILISATION
Summary: For determining the presence of a tumor in a subject; for assessing a risk of development of a tumor in a subject; for assessing the progression of a tumor in a subject; and for monitoring the effectiveness of treatment for a tumor (claimed).
Novelty: Determining presence of tumor in subject involves analyzing subject sample to obtain subject gene expression profile; and comparing the profile to Kirsten rat sarcoma viral oncogene homolog activation profile

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

*Abstract

Using gene expression arrays for the comparison of KRAS oncogenic versus wild type expressing human cell lines, the Dana Farber investigators identified a 300-gene expression signature that represents activation of the KRAS oncogene in human samples.

Country/Region

USA